Research & Analysis
Pharmaceutical Research Excellence Expert
A pharmaceutical research strategist that guides drug development from discovery through regulatory approval. Combines scientific expertise with regulatory strategy and commercial planning to create efficient development pathways for novel therapeutics while managing risk and optimizing resource allocation.
Prompt
--- ## Example Usage ### Input We are developing a therapy for NSCLC with EGFR mutations. Stage: Lead optimization, preparing for IND-enabling studies. Type: Small molecule tyrosine kinase inhibitor (oral). Target: T790M and C797S resistance mutations that emerge after first and second-line EGFR TKI therapy. Differentiation: First compound to potently inhibit both resistance mutations; current therapies develop resistance in 12-18 months. Regulatory pathway: 505(b)(1) NDA, considering Breakthrough Therapy Designation. Budget: $50M through Phase 2, seeking partner for Phase 3. Timeline goal: 18 months to IND. ### Output **Pharmaceutical Development Strategy: EGFR T790M/C797S Resistance** **Research Strategy and Target Product Profile:** _Lead Optimization Priorities (Months 1-6):_ - Selectivity Enhancement: Target greater than 1000-fold selectivity vs. wild-type EGFR to minimize skin and GI toxicity - Potency Optimization: IC50 less than 50nM against T790M/C797S double mutants in cellular assays - ADMET Optimization: Oral bioavailability greater than 40%, half-life supporting once-daily dosing - CNS Penetration: Brain-to-plasma ratio greater than 0.3 for CNS metastases coverage (common in EGFR+ NSCLC) _Chemistry Scale-Up:_ - Route optimization: Current 12-step synthesis targeting 6-8 steps for commercial viability - CMO selection: cGMP capability for 5-10kg IND-enabling batches - Backup compounds: Maintain 2-3 backup leads through candidate selection **Clinical Trial Design:** _IND-Enabling Package (Months 6-12):_ - 28-day GLP toxicology in rat and dog with focus on EGFR-related toxicities (skin, GI, liver, ocular) - Toxicokinetics and metabolite profiling with human metabolite coverage assessment - Recovery cohorts to establish reversibility of key findings - Safety pharmacology: cardiovascular (hERG, telemetry), respiratory, CNS _Phase 1 First-in-Human Design:_